Despite Angi's stock price surge, its P/S ratio stays modest due to underwhelming revenue outlook. Investors see no significant potential for revenue improvement to justify a higher P/S ratio.
Concerns are raised about the company's use of debt due to falling revenue and EBIT loss. The company's balance sheet is seen as risky and its future earnings will be key to maintaining health.
The low P/S ratio of Angi Inc. reflects investor sentiment anticipating the company's limited growth prospects and inferior revenue outlook compared to the industry. Thus, it seems likely that the share price may not rise significantly in the near future.
Doubts linger on Angi Inc.'s transformation, as it grapples with lack of profitability and negative market response to its annual losses. The real question is if its current financial state justifies a long-term rise in share price.
Concern surrounds the company's strained balance sheet and use of debt alongside an EBIT loss. A turn into profit for the recent 12 month loss could bolster confidence in fiscal health. The stock carries considerable risk, and there's a warning sign in Angi's investment analysis.
Due to the current investment shift favoring profits over growth, gig economy stocks have remained challenged, as evidenced by their weak Q2 performance. Provided the notable YoY revenue retardation and drop in service requests, Angi had the weakest Q2 performance.
Gapping up In reaction to earnings/guidance: •$ペプシコ(PEP.US)$+2.8%,$E2オープン ペアレント ホールディングス A(ETWO.US)$+0.7% Other news: •$カンゴ(CANG.US)$+23.5% (approves special dividend of $0.50 per ordinary share or $1 per ADS) •$エル ポーロ ロコ ホールディングス(LOCO.US)$+12.7% (declares $1.50/sh special div; also authorizes new $20 mln share repurchase program) •$KnowBe4(KNBE.US)$+11.4% (KnowBe4 is close to a deal to be acquired by Vista Equity Partners according to ...
Gapping up In reaction to earnings/guidance: •$New Relic(NEWR.US)$+3.8% (guidance),$アメリカン航空(AAL.US)$+2% (guidance) Other news: •$DICE THERAPEUTICS, INC.(DICE.US)$+66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17) •$Albireo Pharma(ALBO.US)$+17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
アンジ Aに関するコメント
📊⚡️📊
In reaction to earnings/guidance:
• $ペプシコ(PEP.US)$+2.8%, $E2オープン ペアレント ホールディングス A(ETWO.US)$ +0.7%
Other news:
• $カンゴ(CANG.US)$ +23.5% (approves special dividend of $0.50 per ordinary share or $1 per ADS)
• $エル ポーロ ロコ ホールディングス(LOCO.US)$ +12.7% (declares $1.50/sh special div; also authorizes new $20 mln share repurchase program)
• $KnowBe4(KNBE.US)$ +11.4% (KnowBe4 is close to a deal to be acquired by Vista Equity Partners according to ...
In reaction to earnings/guidance:
• $New Relic(NEWR.US)$ +3.8% (guidance), $アメリカン航空(AAL.US)$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US)$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US)$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
まだコメントはありません